Zacks Investment Research Upgrades Hill-Rom (HRC) to Buy
Hill-Rom (NYSE:HRC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm currently has a $99.00 price objective on the medical technology company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 12.36% from the company’s previous close.
According to Zacks, “Hill-Rom has been witnessing an increase in revenues on strong international growth. The company is currently focused on gaining traction in the untapped international market on successful execution of its strategy, courtesy its efficient international team and organizational realignment. The company is focusing on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging. Moreover, an improvement in adjusted and operating margin buoys optimism. Overall, Hill-Rom has outperformed the broader industry in the past three months. On the flip side, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.”
HRC has been the topic of several other research reports. Raymond James Financial upgraded Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 price target on the stock in a research note on Wednesday, January 3rd. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. KeyCorp reiterated a “buy” rating and issued a $89.00 price target (up previously from $82.00) on shares of Hill-Rom in a research note on Sunday, November 5th. Stifel Nicolaus reiterated a “buy” rating and issued a $92.00 price target on shares of Hill-Rom in a research note on Wednesday, November 29th. Finally, Needham & Company LLC decreased their price target on Hill-Rom from $93.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday, November 6th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Hill-Rom currently has a consensus rating of “Buy” and a consensus price target of $95.38.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Friday, November 3rd. The medical technology company reported $1.32 EPS for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.05. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. The firm had revenue of $738.30 million for the quarter, compared to analyst estimates of $731.10 million. During the same quarter last year, the company earned $1.18 EPS. The company’s revenue was up 4.6% on a year-over-year basis. equities analysts expect that Hill-Rom will post 4.37 earnings per share for the current year.
In related news, CEO John J. Greisch sold 125,241 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the sale, the chief executive officer now owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John J. Greisch sold 100,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $82.82, for a total value of $8,282,000.00. Following the sale, the chief executive officer now directly owns 230,851 shares in the company, valued at approximately $19,119,079.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 226,241 shares of company stock worth $18,708,644. Corporate insiders own 2.20% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HRC. Seven Eight Capital LP acquired a new stake in shares of Hill-Rom during the 2nd quarter valued at $127,000. Citigroup Inc. boosted its holdings in shares of Hill-Rom by 21.1% during the 2nd quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after acquiring an additional 433 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in shares of Hill-Rom by 101.0% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after acquiring an additional 1,367 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Hill-Rom during the 3rd quarter valued at $207,000. Finally, CAPROCK Group Inc. acquired a new stake in shares of Hill-Rom during the 4th quarter valued at $211,000. 81.92% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Hill-Rom (HRC) to Buy” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/18/zacks-investment-research-upgrades-hill-rom-hrc-to-buy.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.